Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...
Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1...
Khondrion has joined a recently established consortium of universities and industry partners to train international PhD students whose research is...
Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary mitochondrial disease – to move into a Phase III registrational study...
NIJMEGEN, the Netherlands – 25 October 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 14 September 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
We recently sat down with Kasey Woleben, Co-founder, and Sophia Zilber, Board Member and Patient Registry Director of Cure Mito Foundation, to talk...
As 2021 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the past year and the continued progress Khondrion has made in its development of...
Movement, the act or process of moving, the change of place or position or posture, is a complex process under the control of many different parts...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? Jan Smeitink and I have been colleagues since the...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? I first heard about Khondrion from CEO Jan...
Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...
